resTORbio, Inc. Announces Pricing of Public Offering of Common Stock
March 19, 2019 19:32 ET
|
resTORbio, Inc.
BOSTON, March 19, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (“resTORbio” or the “Company”) (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the...
resTORbio, Inc. Announces Proposed Public Offering of Common Stock
March 18, 2019 16:17 ET
|
resTORbio, Inc.
BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. ("resTORbio" or the "Company") (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the...
resTORbio Reports Fourth Quarter and Full Year 2018 Financial Results
March 18, 2019 16:01 ET
|
resTORbio, Inc.
Positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA); Phase 3 program of RTB101 expected to initiate in 2Q19 Phase 1b/2a trial of RTB101 in combination with sirolimus in...
resTORbio Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Global Phase 3 Program for RTB101
March 18, 2019 07:12 ET
|
resTORbio, Inc.
Phase 3 program on track to start enrolling patients in the second quarter of 2019 Data from two Phase 2 clinical trials enrolling more than 900 patients support the design of the Phase 3 program ...
resTORbio to Present at 8th Annual SVB Leerink Global Healthcare Conference
February 21, 2019 08:00 ET
|
resTORbio, Inc.
BOSTON, Feb. 21, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent...
resTORbio Appoints Erkan Baloglu, Ph.D., M.B.A., as Vice President of Drug Discovery and Medicinal Chemistry
February 06, 2019 08:30 ET
|
resTORbio, Inc.
BOSTON, Feb. 06, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent or...
resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition and Neurodegenerative Disease
January 31, 2019 16:30 ET
|
resTORbio, Inc.
BOSTON, Jan. 31, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent or...
resTORbio Appoints William Marshall, M.D., as Vice President of Medical Sciences
December 19, 2018 08:00 ET
|
resTORbio, Inc.
BOSTON, Dec. 19, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio Reports Third Quarter 2018 Financial Results
November 13, 2018 08:00 ET
|
resTORbio, Inc.
Additional positive data from Phase 2b trial further support RTB101’s potential in reducing the incidence of respiratory tract infections (RTIs) in high-risk elderly patients Initiation of pivotal...
resTORbio Co-Founder and Chief Medical Officer Joan Mannick, M.D., to Present on TORC1 Inhibition at The Gerontological Society of America 2018 Annual Scientific Meeting
November 08, 2018 07:12 ET
|
resTORbio, Inc.
BOSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...